<DOC>
	<DOC>NCT02140047</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered with DPT-IPV using ActHIB® as a control in healthy infants.</brief_summary>
	<brief_title>Exploratory Clinical Study of MT-2301</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy infants aged ≥2 and &lt;7 months at the first vaccination of the study drug Written informed consent is obtained from a legal guardian (parent) With obvious pyrexia (axillary temperature of 37.5ºC or higher) at vaccination of the study drug With known serious acute disease With known underlying disease such as cardiovascular disease, renal disease, hepatic disease, blood dyscrasia, and respiratory disease With past diagnosis of immunodeficiency or currently under immunosuppressive treatment History of anaphylaxis due to food or pharmaceuticals With experience of Hib infection, diphtheria, pertussis, tetanus, and acute poliomyelitis With experience of Hib vaccination, or administration of vaccine including either diphtheria, pertussis, tetanus, or polio as a constituent History of convulsions Administered a live vaccine within 27 days before the first vaccination of the study drug, or inactivated vaccine or toxoid within 6 days before vaccination Administered transfusion, immunosuppressant (excluding drugs for external use), or immunoglobulin formulation Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs for external use) continuously for more than 1 week Participated in other studies within 12 weeks before obtaining consent</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Haemophilus influenza type b</keyword>
	<keyword>Hib</keyword>
</DOC>